BPC-157 vs GHK-Cu for Tissue Repair: What the Literature Shows
BPC-157 and GHK-Cu are two of the most studied peptides in tissue repair research. Despite targeting overlapping outcomes, their mechanisms diverge significantly — this article examines each and what the comparative literature suggests.
Research reference only. The information in this article is a summary of peer-reviewed scientific literature. It does not constitute medical advice and is not intended to guide human use. See our full disclaimer.
BPC-157 and GHK-Cu are two of the most extensively studied peptides in preclinical tissue repair research, frequently appearing together in discussions of wound healing and regeneration. Despite producing overlapping outcomes in some study models, their mechanisms are fundamentally distinct — and the evidence base for each maps more strongly to different tissue compartments.
Research reference only. All information on this page is a summary of peer-reviewed scientific literature and does not constitute medical advice. See individual library profiles for full compound data.
BPC-157: Mechanism and Evidence Base
BPC-157 (Body Protection Compound 157) is a synthetic 15-amino acid peptide derived from a partial sequence of human gastric juice protein. It was developed and primarily studied by Predrag Sikiric and colleagues at the University of Zagreb, with hundreds of published studies originating from that research group.
Core Mechanism
The primary mechanistic pathways attributed to BPC-157 in published preclinical studies include:
Nitric oxide (NO) modulation: BPC-157 has been shown to interact with the nitric oxide system bidirectionally — counteracting both NO overproduction (in endotoxic shock models) and deficiency (in vascular injury models). This suggests modulatory rather than simply agonist or antagonist activity.
VEGF/angiogenesis: Multiple rodent studies have documented upregulation of vascular endothelial growth factor (VEGF) and EGR-1 transcription factor following BPC-157 administration, supporting its effects on angiogenesis in wound and tendon repair models.
FAK and paxillin signaling: Chang and colleagues (2011) reported that BPC-157 activates the focal adhesion kinase (FAK) and paxillin signaling pathway in fibroblasts, driving cell migration into injury sites.
Gastrointestinal protection: The compound's most robust published evidence base covers gastric ulcer healing, intestinal anastomosis strength, NSAID-induced GI damage, and inflammatory bowel models — reflecting its origin from gastric tissue research.
Tissue Targets
BPC-157's strongest preclinical evidence covers:
- Tendon and ligament healing: Rat Achilles tendon transection studies (Krivic et al., Journal of Orthopaedic Research, 2006) consistently show faster functional recovery versus controls
- Gastrointestinal repair: Colitis, intestinal fistula, and anastomosis models
- Bone and muscle: Some fracture and crush injury models, though evidence is less consistent than for soft tissue
GHK-Cu: Mechanism and Evidence Base
GHK-Cu (copper tripeptide-1, Gly-His-Lys complexed with Cu²⁺) was first isolated from human plasma albumin by Loren Pickart and colleagues in 1973 (Nature). The copper-bound form is the biologically active species; the free tripeptide has minimal activity without its copper ion.
Core Mechanism
Copper chaperone activity: GHK-Cu facilitates copper delivery to cuproenzymes including lysyl oxidase (critical for collagen and elastin cross-linking) and superoxide dismutase (SOD1). This positions GHK-Cu as an upstream regulator of matrix architecture rather than a direct receptor agonist.
Collagen and extracellular matrix remodeling: Wegrowski and colleagues (1992) demonstrated that GHK-Cu upregulates collagen type I and III synthesis while simultaneously stimulating matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) — suggesting a wound-remodeling rather than simple pro-fibrotic effect.
TGF-beta modulation: Maquart and colleagues (European Journal of Biochemistry, 1999) reported that GHK-Cu downregulates TGF-β1 in fibroblasts at higher concentrations, which may explain its anti-fibrotic effects despite stimulating matrix production at lower concentrations.
Genome-scale transcriptomics: Pickart and Margolina (2018) published a bioinformatics analysis showing GHK tripeptide signature overlapping with over 4,000 human gene expression changes across multiple tissue types, including anti-inflammatory, anti-cancer, and neurotrophin-related pathways — though this indirect evidence requires direct experimental confirmation.
Anti-inflammatory activity: GHK-Cu suppresses TNF-α and IL-6 in macrophage models and reduces oxidative stress markers in multiple tissue systems.
Tissue Targets
GHK-Cu's strongest evidence covers:
- Dermal wound healing: Extensive literature on collagen synthesis, wound contraction, and re-epithelialization in skin models
- Hair follicle stimulation: Scalp tissue and minoxidil-comparison studies
- Lung and nerve tissue: Some preclinical data on lung fibrosis prevention and peripheral nerve regeneration
- Anti-aging skin biology: The largest applied research base, largely from cosmetic-science journals
Head-to-Head Comparison
| Property | BPC-157 | GHK-Cu |
|---|---|---|
| Structure | 15-amino acid synthetic peptide | Tripeptide + copper ion complex |
| Origin | Human gastric juice sequence | Human plasma albumin (Pickart, 1973) |
| Primary mechanism | NO/VEGF/FAK signaling | Copper delivery, MMP/TIMP/collagen regulation |
| Strongest evidence tissue | Tendon, ligament, GI tract | Skin, dermis, hair follicle |
| Anti-inflammatory | YES — systemic anti-inflammatory in multiple models | YES — TNF-α/IL-6 suppression, antioxidant |
| Angiogenesis | Strong (VEGF upregulation, EGR-1) | Moderate (VEGF via copper-dependent enzymes) |
| Collagen synthesis | Indirect (via cell migration/fibroblast activation) | Direct (collagen type I/III upregulation) |
| Oral activity | Some studies suggest partial oral bioavailability | Poor oral bioavailability (metal complex) |
| Human trial data | Minimal (one gastroparesis trial) | Minimal (mostly cosmetic trials) |
| Research group concentration | High (Sikiric lab, Zagreb) | Broader international distribution |
Where the Evidence Diverges
Tendon and Ligament: BPC-157 Leads
For musculoskeletal soft tissue repair — tendons, ligaments, and muscle tears — BPC-157 has a substantially larger and more consistent published evidence base. The Zagreb group's rat tendon transection, rotator cuff, and Achilles repair studies are the most replicated work in this niche.
GHK-Cu has limited published data in these tissues, though its collagen-regulatory effects are plausible mechanistically.
Skin and Dermal Regeneration: GHK-Cu Leads
For dermal wound healing, photoaged skin, and anti-fibrotic effects on skin, GHK-Cu has a longer research history and a more diverse authorship base. Its direct collagen synthesis effects and MMP/TIMP balancing make it the better-characterized peptide for skin biology.
BPC-157 has wound healing data but is not specifically optimized for dermal applications in the literature.
Gastrointestinal: BPC-157 Exclusively
GHK-Cu has no meaningful published literature in gastrointestinal repair. BPC-157's GI evidence base is arguably its strongest domain and the original context for the compound's development.
Research Considerations
Both peptides are studied exclusively in preclinical models and a small number of early-phase human trials. Neither has completed a large, independent, multi-center RCT in human tissue repair. The mechanistic overlap in their anti-inflammatory and angiogenic effects has led some researchers to investigate combined protocols in animal models, though this remains at the exploratory stage.
Researchers interested in these compounds can explore library profiles for BPC-157 and GHK-Cu, as well as the comparison article TB-500 vs BPC-157 for additional tissue repair context.
All content is for research reference purposes only. Not intended as medical advice or to guide human use.